Table 2 TE and major bleeding events according to the antithrombotic treatment, gender and CHADS 2 score
Total (%) | Antithrombotic treatment at the time of event occurrence | |||
|---|---|---|---|---|
| Â | Â | Warfarin* | Antiplatelet | Untreated |
Thromboembolic events | 12 (0.97) | 5 | 6 | 1 |
Stroke | 4 | 2 | 2 | 0 |
TIA | 4 | 1 | 2 | 1 |
Systemic embolism | 4 | 2 | 2 | 0 |
Female | 9 | 4 | 5 | 0 |
Male | 3 | 1 | 1 | 1 |
CHADS2 score | Â | Â | Â | Â |
 0 | 1 | 1 | 0 | 0 |
 1 | 4 | 2 | 1 | 1 |
≥ 2 | 7 | 2 | 5 | 0 |
Major bleeding events | 10 (0.81) | 5 | 5 | 0 |
Intracranial bleeding | 5 | 3 | 2 | 0 |
Systemic bleeding | 5 | 2 | 3 | 0 |
Female | 7 | 5 | 2 | 0 |
Male | 3 | 0 | 3 | 0 |
CHADS2 score | Â | Â | Â | Â |
 0 | 1 | 1 | 0 | 0 |
 1 | 4 | 1 | 3 | 0 |
≥ 2 | 5 | 3 | 2 | 0 |